Sudan Loganathan
Stock Analyst at Stephens & Co.
(0)
# 4450
Out of 5,352 analysts
36
Total ratings
40.74%
Success rate
-11.94%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
BPMC Blueprint Medicines | Downgrades: Equal-Weight | 150 135 | 127.64 | 5.77% | 3 | Jun 3, 2025 | |
ELEV Elevation Oncology | Downgrades: Equal-Weight | 5 5 | 0.3 | 1566.67% | 4 | Mar 24, 2025 | |
IMNM Immunome | Reiterates: Overweight | 30 30 | 9.27 | 223.62% | 2 | Mar 20, 2025 | |
CPRX Catalyst Pharmaceuti... | Reiterates: Overweight | 33 33 | 24.91 | 32.48% | 2 | Feb 27, 2025 | |
ADCT ADC Therapeutics | Maintains: Overweight | 6 8 | 3.58 | 123.46% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 50 50 | 21.66 | 130.84% | 2 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Equal-Weight | 29 29 | 42.64 | -31.99% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Equal-Weight | 15 15 | 8.3 | 80.72% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 31 31 | 12.1 | 156.2% | 3 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 60 60 | 43.58 | 37.68% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 5 5 | 1.68 | 197.62% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 4 | 1.48 | 170.27% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 55 | 6.99 | 686.84% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 13 | 1.33 | 877.44% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 25 25 | 16.18 | 54.51% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 5 5 | 0.34 | 1370.59% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 2.12 | 843.4% | 1 | May 14, 2024 |